Liquid formulations, including & GT; 7% propylene glycol and: a defined non-prolonging agent, or a fixed angiotensin converting enzyme inhibitor, or combination of both; preparation process; toolkit; drugs for heart disease and/or hypertension.
The invention relates to a liquid formulation comprising propylene glycol and an effective amount of an inodilator, an angiotensin converting enzyme inhibitor, or a combination of an inodilator and an angiotensin converting enzyme inhibitor and to use of the formulation for treating cardiac disease and/or hypertension.FORMULACIÓN LÍQUIDA QUE COMPRENDE >;7% DE PROPILENGLICOL Y: UN INODILATADOR DEFINIDO, O UN INHIBIDOR DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA DEFINIDO O UNA COMBINACIÓN DE AMBOS; PROCESO DE PREPARACIÓN; KIT; USO PARA TRATAR LA ENFERMEDAD CARDÍACA Y/O HIPERTENSIÓN.